$PAMT

Pamt Corp. books another net loss, 110.6% adjusted TL OR

Pamt Corp. reported a net loss and said consolidated revenue rose 9% year over year to $165 million, or 2% excluding fuel surcharges. Truckload revenue fell 7% y/y (ex-fuel) with fewer trucks in service. TL operating ratio was 110.6% excluding a one-time insurance accrual. Logistics revenue was $51 million, up 24% y/y.

Original reporting
Published Aug 5, 2026, 12:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 3:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pamt Corp. books another net loss, 110.6% adjusted TL OR — source image
Decision brief

The 30-second read

$PAMTBearishMed
01

Why it matters

Traders may reprice near-term profitability expectations based on continued TL operating losses (11 straight) and mixed operating trends (loaded miles up, revenue per loaded mile down ex-fuel). The logistics unit’s improved OR provides some diversification support.

02

Market read

Fresh quarterly operating and liquidity details plus a CFO appointment can shift estimates for carrier profitability and credit risk.

03

What to watch

Liquidity declined and debt rose in the first half, which may matter more for credit risk than the headline revenue growth.

Relevance 7/10Novelty 6/10Timing: today’s reported quarter results and CFO appointment

Background

The article frames Pamt’s results as an example of carriers cutting fleet counts to improve profitability amid pressured rates and persistent inflationary costs.

Company-level read

Ticker impact

$PAMTBearishMedium confidence
Context

Pamt reported another truckload operating loss, with TL operating ratio 110.6% excluding a one-time insurance accrual, plus 11 straight TL operating losses.

Expected impact

Near-term downside bias as traders focus on continued TL operating losses and weaker ex-fuel revenue per loaded mile.

Evidence & confidence

The article discloses multiple profitability and operating-metric datapoints (OR, revenue trends, fleet count, liquidity/debt) that can drive sentiment and estimates, even without a guidance change.

Market effects

Highlights ongoing truckload pricing pressure and driver-supply constraints, reinforcing a cautious read-through for carrier margins.

No specific regional demand signal provided.

Limited global linkage; primarily US trucking/carrier profitability dynamics.

Counterpoint

The sequential rate per total mile improvement and better adjusted OR year over year could indicate a turning point despite continued losses.

Key entities

  • Pamt Corp.

    Reported consolidated revenue growth, truckload operating ratio deterioration/excluding accrual, logistics margin improvement, and appointed a new CFO.

  • Daniel Kleine

    Appointed chief financial officer, previously VP of tax and later senior VP of finance and treasurer.

  • Lance Stewart

    President who commented on sequential rate per total mile improvement and continued rate-correction opportunities.

Related articles

$PAMTMed

PAMT CORP (PAMT): ANNOUNCES RESULTS FOR THE SECOND QUARTER

PAMT CORP (PAMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PAMT CORP ANNOUNCES RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 Second Quarter 2026 Summary Results ● Total revenues of $164.7 million, up 8.9% YoY ● Operating loss of $10.4 million ● Operating ratio of 106.3% ● Net loss of $7.4 million ● Diluted loss per shar

SK hynix Rebounds 4.42% as Solidigm Listing Is Shelved

SK hynix (000660) shares rose 4.42% after the company abandoned plans to list its U.S. subsidiary, Solidigm. The move eased concerns about a dual-listing discount and stake dilution. Brokerages maintain high target prices, with Nomura setting it at 4.7 million won. Investors await the company's earnings release on the 28th for further guidance.

Med

AI neocloud stocks sink as CoreWeave debt fears spread to equities

CoreWeave's stock dropped 38% in October, cutting its market value to $30B from a peak of $90B. Nebius and IREN also fell sharply. CoreWeave's debt concerns, including high-yield bonds and potential GPU collateral depreciation, triggered the selloff. Gartner's report on neocloud sector risks further pressured stocks. Nvidia's financing role adds uncertainty.

$IBBMedAI 8/10

Biotech ETF Rises 23% as Drug Milestones Span Trials to Approval

The iShares Biotechnology ETF (IBB) rose 23.1% through Oct. 23, driven by drug milestones. Merck and Moderna reported positive Phase 3 trial data for intismeran autogene. Roche's Enspryng gained FDA approval for thyroid eye disease. Eli Lilly plans to submit a weight-loss drug for FDA review in early 2027. IBB's expense ratio is 0.44%, while SPDR S&P Biotech ETF (XBI) has a 0.35% expense ratio.

$CRWDMed

CrowdStrike’s CEO Says a Wave of Cyber Attacks Are Coming

CrowdStrike's CEO warned of impending cyberattacks due to PHP vulnerabilities, leading to an 8.25% stock price increase. Palo Alto Networks and other cybersecurity firms also saw gains. The flaws could impact millions of servers, with AI-powered attacks on the rise. CrowdStrike's professional services revenue reached $71 million last quarter, while Palo Alto's firewalls offer rapid protection against new threats.